London-based Hormona, a HealthTech company using AI and at-home testing to help women track, understand and optimise their hormones, has raised a €7.8 million Seed round to fuel their expansion and help launch its hormone tests.
The round was led by Voima Ventures (Helsinki) and co-led by SuperNode Global VC (London). The round also received backing from DLF Ventures, as well as previous investors, Swedish Nascent Invest and Techstars in the US.
Hormona CEO and Co-founder Karolina Löfqvist comments: “For too long, women have had to suffer through hormonal issues, relying on trial and error and waiting until symptoms become unbearable. That’s no way to live. We built Hormona to change that – to give women control over their hormonal health without having to spend years suffering, as I did. This investment brings us one step closer to making real-time hormone tracking accessible to women everywhere without the need for multiple blood draws. We’re proud to be leading the way and improving women’s health, one user at a time.”
Founded in 2020, Hormona is a women’s health company using AI and at-home testing to empower women to understand and manage their hormone health. Co-founded by Karolina Löfqvist (CEO) and Jasmine Tagesson (COO), Hormona provides personalised hormone tracking and expert-backed guidance to help women address hormonal imbalances and related conditions.
The company collaborates with a team of endocrinologists, gynaecologists, and nutritionists to deliver science-backed insights. With a team of 12, Hormona has raised €10.2 million in total funding. Hormona was created with clinical experts in endocrinology, gynecology and nutrition to help users manage hormone-related conditions and better understand their health.
The company was inspired by Löfqvist’s personal experience, in which a common hormonal condition derailed her life and went undiagnosed for years despite seeking extensive medical help. Hormona says Löfqvist’s story is far from unique, with 80% of women experience hormone-related issues.
Inka Mero, Managing Partner and Founder at Voima Ventures adds: “At Voima Ventures, we seek out visionary teams and bold science that can redefine entire industries, and Hormona is exactly that: they are pioneering a global movement in women’s health. By tackling one of the most overlooked yet fundamental aspects of women’s well-being – hormonal health – they are giving millions of women the tools, data, and empowerment to take control of their bodies and lives. We are incredibly proud to stand beside Hormona as they lead this health revolution.”
Hormona has spent the last four years developing the “first fully quantitative hormone tests of their kind“, covering the full clinical range. With over 90% accuracy compared to traditional venous blood sampling, Hormona wants to pioneer a new, much more accessible way to track hormonal health.
Beyond the tests, Hormona’s app, which educates women on hormonal issues, has been downloaded in 190+ countries. The app is experiencing 30% month-over-month growth, while 80% of users remain active after 12 months.
Gina King, Partner at SuperNode Global VC comments: “The future of women’s health is proactive, data-driven, and deeply personalised – and Hormona is making that future a reality. They’re bringing cutting-edge innovation to an area long overlooked by investment and technology, turning hormone health from guesswork into precision. At Supernode Global, we invest in companies that empower people in how they live – and Hormona exemplifies that mission. By providing women with insights that were once out of reach, Hormona is transforming the landscape of healthcare. They represent exactly the kind of world-changing platform we’re proud to support as they scale globally and help millions of women live to their fullest potential.”
Hormona believes that women’s health remains severely underfunded, underresearched and underserved. Just 2% of global medical funding goes towards researching issues specific to women. Meanwhile, in equity investment, all-female Founder teams in the UK received 2% of total equity investment last year, down from 2.5% in 2023.
Unlike traditional hormone tests, which Hormona says cost around €177 for a one-time test, Hormona reportedly offers affordable, continuous tracking without the need for a lab. This contributes to a wider gender health gap where women spend 25% more of their lives in poor health than men.
Hormona is free to download on iOS and Android, with a premium version (Hormona+) offering tailored cycle predictions and health programmes too reduce hormonal imbalance symptoms. Other Hormona offerings include cycle-specific lifestyle tips, symptom reduction plans, and supplements. Users can also invite their partners to receive phase-specific email updates with insights and tips on how to support them.
Inka Mero (Voima Ventures), who has invested in multiple HealthTech and mission-driven startups, and Gina King (SuperNode), a founding member of the female executive network Chief, will also join Hormona’s all-female board to support its next phase of growth.
Read the orginal article: https://www.eu-startups.com/2025/05/hormona-a-healthtech-startup-enabling-women-to-track-understand-and-optimise-their-hormones-raises-e7-8-million/
